RGI-2001用于异基因造血干细胞移植后急性移植物抗宿主病的预防
这项开放标签、多中心2b期试验评估了RGI-2001联合标准GVHD预防方案在清髓性异基因造血干细胞移植受者中的安全性和疗效。49例受者接受RGI-2001 100 μg/kg每周一次共6次联合他克莫司和甲氨蝶呤,第100天2-4级急性GVHD累积发生率为24.9%,3-4级为4.1%。与CIBMTR登记组对照相比,第180天2-4级急性GVHD无病生存率为70.8% vs 50.7%(校正HR 0.45,95%CI 0.30-0.68)。
要点
- RGI-2001 100 μg/kg每周一次共6次联合他克莫司和甲氨蝶呤耐受良好,无严重输注反应。
- 16例发生≥3级治疗相关不良事件,包括食欲下降、白细胞减少、血小板减少和口腔炎。
- 第100天2-4级急性GVHD累积发生率24.9%,3-4级为4.1%,移植后观察到NKT和Treg细胞群增加。
核心结论
- RGI-2001耐受良好,与清髓性造血干细胞移植后较低的急性GVHD发生率和令人鼓舞的生存相关。
- 结果支持靶向NKT和Treg细胞群以增强异基因造血干细胞移植受者免疫变化的策略。
研究设计与样本
- 开放标签、多中心2b期试验,评估RGI-2001联合标准GVHD预防方案在接受清髓性异基因造血干细胞移植受者中的安全性和疗效。
- RGI-2001以100 μg/kg剂量输注,每周一次共6次。
- 主要终点为第100天2-4级急性GVHD。
- 共49例受者接受RGI-2001联合他克莫司和甲氨蝶呤。
- 试验注册号NCT04014790。
主要发现
- RGI-2001耐受良好,无严重输注反应。
- 16例受者发生≥3级治疗相关不良事件,包括食欲下降、白细胞减少、血小板减少和口腔炎。
- 2-4级急性GVHD累积发生率为24.9%,3-4级为4.1%。
- 与CIBMTR登记组对照相比,接受RGI-2001的受者第180天2-4级急性GVHD无病生存率为70.8% vs 50.7%(校正HR 0.45,95%CI 0.30-0.68)。
- 移植后观察到NKT和Treg细胞群增加,与RGI-2001的拟定作用一致。
关键数值与推荐
- RGI-2001剂量为100 μg/kg,每周一次共6次。
- 主要终点第100天2-4级急性GVHD累积发生率为24.9%,3-4级为4.1%。
- 第180天2-4级急性GVHD无病生存率:RGI-2001组70.8% vs CIBMTR对照组50.7%(校正HR 0.45,95%CI 0.30-0.68)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RGI-2001, a glycolipid that binds CD1d receptor of antigen-presenting cells, can activate invariant natural killer T (NKT) cells and stimulate cytokine-dependent proliferation of regulatory T cells (Tregs). This open-label, multicenter phase 2b trial evaluated the safety and efficacy of RGI-2001 in combination with standard graft-versus-host disease (GVHD) prophylaxis in participants receiving myeloablative allogeneic hematopoietic cell transplantation (HCT). RGI-2001 was infused at a dose of 100 μg/kg for 6 weekly doses. The primary end point was grade 2 to 4 acute GVHD by day 100. A total of 49 participants received RGI-2001 in combination with tacrolimus and methotrexate. RGI-2001 was well tolerated, with no serious infusion reactions. Sixteen participants experienced grade ≥3 treatment-related adverse events, including decreased appetite, leukopenia, thrombocytopenia, and stomatitis. The cumulative incidence of grade 2 to 4 and 3 to 4 acute GVHD were 24.9% and 4.1%, respectively. Compared with the controls from the Center for International Blood and Marrow Research Transplant registry, participants receiving RGI-2001 experienced superior clinical outcomes, including day-180 grade 2 to 4 acute GVHD-free survival (70.8% vs 50.7%; adjusted hazard ratio, 0.45; 95% confidence interval, 0.30-0.68). Increasing NKT and Treg populations were observed after HCT, consistent with the proposed action of RGI-2001. In conclusion, RGI-2001 was well tolerated and was associated with low rates of acute GVHD and encouraging survival after myeloablative HCT. These results support strategies that target NKT and Treg cell populations to augment immunologic changes in allogeneic HCT recipients. This trial was registered at www.clinicaltrials.gov as #NCT04014790.
引用
- DeFilipp Z, Choe H, Efebera YA, et al. RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT. Blood. 2025. PMID: 40680268. doi:10.1182/blood.2025029584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。